

Laura Daugherty

Disclosure has not been provided.

Sara Ahmed

Disclosure has not been provided.

Andrea Allen

Participant discloses the following financial or non-financial relationships:

1. United Therapeutics: Speaker's Bureau, Consultant
2. Gilead: Speaker's Bureau, Consultant
3. Bayer: Speaker's Bureau, Consultant

Participant has indicated no discussion of unapproved drug or product uses.

Julie Anderson, RN, CCRN

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Dr. Rebekah Anguiano, PharmD, BCPS, BCACP

Participant discloses the following financial or non-financial relationships:

1. United Therapeutics: Speakers Bureau

Participant has indicated no discussion of unapproved drug or product uses.

Dr. Rana L. A. Awdish, MD

Participant discloses the following financial or non-financial relationships:

1. Actelion Pharmaceutical Inc. : Research Grantee
2. United Therapeutics Corporation: Research Grantee
3. Bayer HealthCare: Research and Speakers Bureau

Participant has indicated no discussion of unapproved drug or product uses.

Nancy Bair, RN, MSN, APRN, CNS-BC

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Andrea Gergay Baird, MSW, LCSW

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Christopher Barnett

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Jennifer Beier, RN, MSN, CPNP-PC

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated the following discussion of unapproved drug or product uses:

Treprostinil in infants

Dr Raymond Benza

Participant discloses the following financial or non-financial relationships:

1. Bayer AG: Grant

Participant has indicated no discussion of unapproved drug or product uses.

Dr. Anirban Bhattacharyya, MD, MPH

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Dr. David C. Booth, MD

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Daniela Brady, FNP

Disclosure has not been provided.

Laura Bryan, N.P.

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Anna Bustin, PharmD

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated the following discussion of unapproved drug or product uses:

Treprostinil IV use is not FDA labeled for pediatrics

Ms Olivia Carter, MSN, RN-BC, PCCN

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Michelle Cash, M.S.N., R.N., CNP

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated the following discussion of unapproved drug or product uses:

PDE5s, ERA, Prostacyclins d/t age restrictions

Murali Chakinala

Participant discloses the following financial or non-financial relationships:

1. Actelion, Gilead, United Therapeutics, Bayer, Medtronic, Novartis AG, Ikaria, SteadyMed Therapeutics, Reata Pharmaceuticals, and Express Scripts: Murali Chakinala has received consulting fees, speaker fees, and/or grant monies from Actelion, Gilead, United Therapeutics, Bayer, Medtronic, Novartis AG, Ikaria, SteadyMed Therapeutics, and Reata Pharmaceuticals; and is a board or advisory committee member for Actelion, Gilead, Bayer, United Therapeutics, and Express Scripts.

Participant has indicated no discussion of unapproved drug or product uses.

Dr. Mahesh Chandrasekhar, MD

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Dr. Richard Channick, M.D.

Participant discloses the following financial or non-financial relationships:

1. Actelion: Consultant, research grants
2. Bayer: consultant, research grants
3. Arena: Consultant

Participant has indicated no discussion of unapproved drug or product uses.

Kelly Chin

Participant discloses the following financial or non-financial relationships:

1. Actelion: Consulting and institutional research support
2. Bayer: Institutional research support
3. United therapeutics: Consulting and institutional research support
4. GeNO: Institutional research support
5. Sonivie: Institutional research support
6. NIH: Research support

Participant has indicated no discussion of unapproved drug or product uses.

Elizabeth Colglazier, MS, CPNP-AC

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated the following discussion of unapproved drug or product uses:

I will be discussing the use of subcutaneous treprostinil in pediatric patients

Prof Paul Corris

Participant discloses the following financial or non-financial relationships:

1. Bayer: Grant, personal fees, university research fund
2. Actelion: Personal fees
3. GSK: Personal fees

Participant has indicated no discussion of unapproved drug or product uses.

Lesley D'Albini

Disclosure has not been provided.

Anne Davis, R.N.

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated the following discussion of unapproved drug or product uses:

Orenitram is not FDA approved for use in pediatrics. I reference the use of Orenitram in pediatric patients.

Mrs Julie Dias, RN

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Mrs Johnell M Diwan, BSN, RN

Participant discloses the following financial or non-financial relationships:

1. United Therapeutics : Speakers Bureau
2. Actelion : Speakers Bureau
3. Bayer : S

Participant has indicated no discussion of unapproved drug or product uses.

Jaclyn Doyle, MS, APRN, NP-BC

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Dr. Hilary DuBrock, MD, MMSc

Participant discloses the following financial or non-financial relationships:

1. United Therapeutics: Principal Investigator in sponsored clinical trials

Participant has indicated the following discussion of unapproved drug or product uses:

I will discuss off-label use of midodrine.

Dr. Laura Duvall, PharmD, BCPS

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Dr. C. Gregory Elliott, MD, MACP, FCCP

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Heidi Erickson, BSN, RN

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Dr. Karen Fagan, MD

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Harrison Farber

Participant discloses the following financial or non-financial relationships:

1. Speaker for Gilead Sciences, Inc., Bayer Corporation and Actelion Pharmaceuticals US, Inc.; Steering Committee, board or advisory committee member for Actelion Pharmaceuticals US, Inc., Gilead Sciences, Inc., Bayer Corporation, Bellerophon Therapeutics, Inc., and United Therapeutics Corporation/Lung LLC; Research support from Gilead Sciences, Inc., Actelion Pharmaceuticals US, Inc. and United Therapeutics Corporation: Speaker; steering committee member; advisory board member; and research support

Participant has indicated no discussion of unapproved drug or product uses.

Adrian Felder, MSN, RN

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Dr. Paul Forfia, MD

Disclosure has not been provided.

Kathy Galvin, ANP-C, CHFNP

Participant discloses the following financial or non-financial relationships:

1. Gilead Pharmaceuticals: speaker
2. Actelion Pharmaceuticals: speaker

Participant has indicated no discussion of unapproved drug or product uses.

Dr. Ahmed M Gharib

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Professor Hossein-Ardeschir Ghofrani

Participant discloses the following financial or non-financial relationships:

1. Actelion: Grant and personal fees (Board membership, consultancy, paid lectures and travel/accomodation expenses)
2. Bayer AG: Grant and personal fees (Board membership, consultancy, paid lectures and travel/accomodation expenses)
3. GSK: Personal fees (Board membership, consultancy, paid lectures and travel/accomodation expenses)
4. Novartis: Grant and personal fees (Board membership, consultancy, paid lectures and travel/accomodation expenses)
5. Pfizer: Grant and personal fees (Board membership, consultancy, paid lectures and travel/accomodation expenses)
6. Ballephron: Personal fees (consultancy)
7. United Therapeutics: Personal fees (consultancy, paid lectures and travel/accomodation expenses)

Participant has indicated no discussion of unapproved drug or product uses.

Dr J Simon R Gibbs

Participant discloses the following financial or non-financial relationships:

1. Actelion Pharmaceuticals: Grants, personal fees and other
2. Bayer AG: Personal fees and other
3. GSK: Personal fees and other
4. Bellerophon: Personal fees
5. Merck Sharpe & Dohme: Personal fees
6. Pfizer: Personal fees
7. AOP Orphan: Personal fees

Participant has indicated no discussion of unapproved drug or product uses.

Dr. R. Mark Grady, MD

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Mrs Patricia Marie Gresham, MSN, ANP-BC, CCRN

Participant discloses the following financial or non-financial relationships:

1. United Therapeutics: consultant
2. Bayer: consultant/ speaker
3. Gilead: consultant

Participant has indicated no discussion of unapproved drug or product uses.

Hunter Groninger, M.D.

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Lillian Hansen, NP-C, MSN, MS, MEd

Participant discloses the following financial or non-financial relationships:

1. United Therapeutics: speaker's bureau member, consultant
2. Bayer : speaker's bureau member, consultant
3. Actelion: speaker's bureua member, consultant

Participant has indicated no discussion of unapproved drug or product uses.

Scarlett Harden, ACNP-BC

Participant discloses the following financial or non-financial relationships:

1. Gilead : Advisory Board on 10/3/17

Participant has indicated no discussion of unapproved drug or product uses.

Mrs. Starlet Harrimon, BSN, RN-BC

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Elise Hazlewood

Disclosure has not been provided.

Gustavo Heresi, M.D., M.S.

Participant discloses the following financial or non-financial relationships:

1. Bayer Healthcare: Advisory Board and Speaker's Bureau

Participant has indicated no discussion of unapproved drug or product uses.

Dr. Kristin B. Highland, MD, MSCR

Participant discloses the following financial or non-financial relationships:

1. Actelion Pharmaceuticals: Speaker's Bureau, Consultant, Grants and Contracts
2. Bayer Healthcare: Speaker's Bureau, Consultant, Grants and Contracts
3. Gilead Sciences: Speaker's Bureau
4. United Therapeutics: Speaker's Bureau, Grants and Contracts
5. Eiger Pharmaceuticals: Grants and Contracts
6. Reata Pharmaceuticals: Grants and Contracts
7. Boehringer Ingelheim: Speaker's Bureau, Consultant, Grants and Contracts

Participant has indicated no discussion of unapproved drug or product uses.

Russel Hirsch, M.D.

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Dr. William E. Hopkins, MD

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Lauren Hulett, MBA, BSN, RN

Participant discloses the following financial or non-financial relationships:

1. Bayer Healthcare: Informational Speaker

Participant has indicated no discussion of unapproved drug or product uses.

Dr. Javier Jimenez, MD, PhD, FACC

Participant discloses the following financial or non-financial relationships:

1. Actelion: Speaker/Advisory
2. United Therapeutics: Speaker/Advisory
3. Bayer: Speaker/Advisory
4. Gilead: Advisory

Participant has indicated the following discussion of unapproved drug or product uses:

CardioMEMS Chronicle Medtronic

Kelsey Lovett Johnson ADN, RN, ADN, RN

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Anil Jonnalagadda

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Dr. Kim M. Kerr, MD

Participant discloses the following financial or non-financial relationships:

1. Bayer: Research support (U.S. CTEPH Registry) and travel funding to present at educational forums

Participant has indicated the following discussion of unapproved drug or product uses:

Yes, I will present observations from the U.S. CTEPH Registry of off label use of PAH medications in operable CTEPH patients

Mrs Amy Kimber, RN, APNP

Participant discloses the following financial or non-financial relationships:

1. Actelion: Advisory Board
2. Bayer: Advisory Board
3. Prime Education LLC: Speaker for webinars

Participant has indicated no discussion of unapproved drug or product uses.

Dr. Martha Kingman, FNP-C, DNP

Participant discloses the following financial or non-financial relationships:

1. Actelion: Speaker Bureau, Advisory Board
2. Bayer: Speaker Bureau, Advisory Board
3. Gilead: Speaker Bureau, Advisory Board
4. United Therapeutics: Speaker Bureau, Advisory Board

Participant has indicated no discussion of unapproved drug or product uses.

Dr. Kevin Kissling, PharmD, BCPS

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Dr. James R Klinger, MD

Participant discloses the following financial or non-financial relationships:

1. Actelion: Grant Support
2. Eiger: Grant Support
3. Lung International: Grant Support
4. United Therapeutics: Grant Support
5. Bayer: Grant Support/consultant

Participant has indicated no discussion of unapproved drug or product uses.

Dr David Langleben

Participant discloses the following financial or non-financial relationships:

1. Bayer Healthcare Pharmaceuticals: Personal fees, non-financial support
2. Actelion: Personal fees, non-financial support
3. Gilead: Personal fees, non-financial support
4. GSK: Personal fees, non-financial support
5. Ikaria: Personal fees, non-financial support

Participant has indicated no discussion of unapproved drug or product uses.

Patricia Lawrence, MSN, CPNP-AC/PC

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Shea Liput

Disclosure has not been provided.

Spencer Liu

Disclosure has not been provided.

Ms. Sandra Lombardi

Participant discloses the following financial or non-financial relationships:

1. Actelion and Bayer: Consultant, Speaker for both Actelion and Bayer

Participant has indicated no discussion of unapproved drug or product uses.

Mrs Allison Lynn, RN, BSN, PCCN

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Prof. Hoepfer Marius

Participant discloses the following financial or non-financial relationships:

1. Actelion: Personal fees (Lectures and consultations)
2. Bayer AG: Personal fees (Lectures and consultations)
3. Gilead: Personal fees (Lectures and consultations)
4. GSK: Personal fees (Lectures and consultations)
5. Pfizer: Personal fees (Lectures and consultations)
6. MSD: Personal fees (Lectures and consultations)

Participant has indicated no discussion of unapproved drug or product uses.

Natalie Marsh

Disclosure has not been provided.

Erica McCluskey

Disclosure has not been provided.

Vallerie McLaughlin

Participant discloses the following financial or non-financial relationships:

1. Actelion: Grant, personal fees and non-financial support
2. Bayer AG: Grant, personal fees and non-financial support
3. Gilead: Grant, personal fees and non-financial support
4. United Therapeutics: Grant, personal fees and non-financial support
5. Ikaria: Grant, personal fees and non-financial support

6. Novartis: Grant

Participant has indicated no discussion of unapproved drug or product uses.

Selma Mohammed, MD, PhD

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Dr Robert Naeije

Participant discloses the following financial or non-financial relationships:

1. Actelion: Personal fees and advisory board member fees
2. GSK: Personal fees
3. Bayer AG: Advisory board member fees
4. Lung Biotechnology Corporation: Advisory board member fees
5. Reata: Grant

Participant has indicated no discussion of unapproved drug or product uses.

Mark Robert Nicolls

Disclosure has not been provided.

Emma Olson, MS, RN, C-PNP

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated the following discussion of unapproved drug or product uses:

treprostinil, sildenafil, bosentan, iloprost

Sara Paulus, PA-C

Participant discloses the following financial or non-financial relationships:

1. Bayer: Advisory Committee
2. United Therapeutics: Advisory Committee; Consultant

Participant has indicated no discussion of unapproved drug or product uses.

Prof. Andrew Peacock

Participant discloses the following financial or non-financial relationships:

1. Actelion: Grants (research, honoraria) and personal fees (meetings)
2. Bayer AG : Grants (research, honoraria) and personal fees (meetings)
3. GSK: Grants (research, honoraria) and personal fees (meetings)
4. Pfizer: Grants (research, honoraria) and personal fees (meetings)

Participant has indicated no discussion of unapproved drug or product uses.

Lisa Peters

Disclosure has not been provided.

Dr. Carla Pies, DNP, ARNP, ACHPN

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Dr. David Poch, M.D.

Participant discloses the following financial or non-financial relationships:

1. Bayer Pharmaceuticals: Speaker/Consultant

Participant has indicated no discussion of unapproved drug or product uses.

Abby Poms, RRT, CCRP

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Dr. Amresh Raina, MD, FACC

Participant discloses the following financial or non-financial relationships:

1. Bayer: Speaker
2. Abbott/St. Jude: Consultant

Participant has indicated the following discussion of unapproved drug or product uses:

I agree. My presentation includes use of cardioMEMS in pulmonary arterial hypertension which is off label.

Dr. Ashwin Ravichandran, MD, MPH, FACC

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Dr. Franz Rischard, DO, MS

Participant discloses the following financial or non-financial relationships:

1. Gilead: Advisory boards, Research Support, consultant
2. United Therapeutics : Advisory boards, Research Support, consultant
3. Bayer : Advisory boards, Research Support, consultant
4. Actelion : Advisory boards, Research Support, consultant

Participant has indicated no discussion of unapproved drug or product uses.

Fran Rogers, MSN, CRNP

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Professor Stephan Rosenkranz

Participant discloses the following financial or non-financial relationships:

1. Actelion: Grant and personal fees
2. Bayer AG: Grant and personal fees
3. Gilead: Personal fees
4. GSK: Personal fees
5. Novartis: Grant and personal fees
6. Pfizer: Grant and personal fees
7. United Therapeutics: Grant and personal fees

Participant has indicated no discussion of unapproved drug or product uses.

Mrs Stephanie Anna Ruen, MSN, RN, CCNS, CCRN

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Dr. James Runo, MD

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Allyson Rupp, MSW, LCSW

Participant discloses the following financial or non-financial relationships:

1. Guidemark Health through Actelion: Beyond the Basics Faculty

Participant has indicated no discussion of unapproved drug or product uses.

Michael Salinero, R.N., BSN

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Dr Pablo G Sanchez, MD, PhD

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated the following discussion of unapproved drug or product uses:

Ex vivo lung perfusion systems are under clinical trials for FDA approval

Laura Savage

Disclosure has not been provided.

Dr Riccardo Scagliola, M.D.

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Dr. Robert Schilz, DO, PhD

Participant discloses the following financial or non-financial relationships:

1. Actelion: Speakers Bureau, Consultant, Research Grants
2. Bayer: Speakers Bureau
3. Arena: Research Grant
4. Gilead: Speakers Bureau
5. United Therapeutics: Speakers Bureau, Consultant, Research Support

Participant has indicated no discussion of unapproved drug or product uses.

Ann Schmit, R.N., B.S.N.

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Maureen Seckel, APRN, ACNS-BC, CCNS, CCRN, FCCM

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Dr. Trushil Shah, MD, MS

Participant discloses the following financial or non-financial relationships:

1. Gilead sciences: Advisory board and speakers bureau member
2. Actelion pharmaceuticals: Site Principal Investigator for research registry
3. Bayer Pharmaceuticals: Site Principal Investigator for research trial

Participant has indicated no discussion of unapproved drug or product uses.

Professor Gerald Simmoneau

Participant discloses the following financial or non-financial relationships:

1. Actelion: Grant and personal fees
2. Bayer AG: Grant and personal fees
3. GSK: Grant and personal fees
4. Novartis: Grant and personal fees
5. Lilly: Grant and personal fees
6. Pfizer: Non-financial support

Participant has indicated no discussion of unapproved drug or product uses.

Miss Megan Smakulski, MSN, MBA, RN, PCCN

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Traci Stewart, RN, MSN, CHFN

Participant discloses the following financial or non-financial relationships:

1. Actelion: Nurse Advisor
2. Bayer Healthcare: Nurse Advisor
3. Gilead: Nurse Consultant

Participant has indicated no discussion of unapproved drug or product uses.

Dr Roxana Sulica

Participant discloses the following financial or non-financial relationships:

1. Actelion: Grant, personal fees (consultation, advisory board)
2. Bellerophon Therapeutics: Research support
3. Lung Biotechnology: Research support
4. Bayer HealthCare Pharmaceuticals: Personal fees (consultation, advisory board)
5. Gilead Sciences: Personal fees (advisory board)
6. United Therapeutics: Personal fees (consultation)
7. Reata: Research support

Participant has indicated no discussion of unapproved drug or product uses.

Victor Tapson, MD

Participant discloses the following financial or non-financial relationships:

1. Actelion: Research, consulting
2. Bayer: Research, consulting
3. Arena: Research
4. Reata: Research, consulting
5. Gilead: Consulting
6. United Therapeutics: Research, consulting
7. V Wave Medical: Consulting

Participant has indicated the following discussion of unapproved drug or product uses:

I have no current intention to do so, but if I do I will state that it is off-label.

Nimi Tarango, RN, MS, NP-BC

Participant discloses the following financial or non-financial relationships:

1. Actelion Pharmaceuticals: Speaker; Advisory board participant
2. Gilead Sciences: Advisory board participant

Participant has indicated no discussion of unapproved drug or product uses.

Christopher Thomas, PharmD, EMBA, BCPPS

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated the following discussion of unapproved drug or product uses:

Y

Dr Adriano Tonelli, MD, MSc

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Dr. Fernando Torres, MD

Participant discloses the following financial or non-financial relationships:

1. Gilead: Research
2. Actelion/Johnson and Johnson: Consultant, Speaker
3. United Therapeutics: Research
4. Bayer: Consultant, Speaker
5. Mallinckrodt: Consultant
6. Genentech: Speaker
7. Boehringer: Advisor
8. Peloton: Consultant
9. Arena: Consultant and research
10. Reata: Consultant
11. GeNO: research
12. Eiger: Research

Participant has indicated no discussion of unapproved drug or product uses.

Julie Tracy, MSc

Participant has no financial or non-financial arrangements or affiliations to disclose.

Dr. Scott Visovatti, MD

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Mrs. Tania Von Visger, APRN, CNS, CCNS, PCCN

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

pmr Anton Vonk-Noordegraaf

Participant discloses the following financial or non-financial relationships:

1. actelion: speakersfee
2. msd: speakersfee

Participant has indicated no discussion of unapproved drug or product uses.

Lisa Wheeler, BSMT

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.

Mary Elizabeth Whittenhall, MSN, APRN, AGACNP-BC

Participant discloses the following financial or non-financial relationships:

1. United Therapeutics: Speakers Bureau

Participant has indicated no discussion of unapproved drug or product uses.

Melisa Wilson, MSN, ARNP, ACNP, BC

Participant discloses the following financial or non-financial relationships:

1. United Therapeutics: Speaker, Advisor
2. Actelion: Speaker
3. Bayer: Speaker

Participant has indicated no discussion of unapproved drug or product uses.

Amber Young, MD

Participant discloses the following financial or non-financial relationships:

1. NIH Rheumatology Training Grant 5T32AR007080-38: Salary Support as Trainee

Participant has indicated no discussion of unapproved drug or product uses.

Dr. Delphine Yung, MD

Participant discloses the following financial or non-financial relationships:

1. United Therapeutics: research contract, clinical trial consultant
2. Eli Lilly: clinical trial DSMB

Participant has indicated the following discussion of unapproved drug or product uses:

epoprostenol, treprostinil, sildenafil, tadalafil, ambrisentan, macitentan, selexipag

Roham Zamanian

Disclosure has not been provided.

Tonya Zeiger, RRT, CPFT

Participant has no financial or non-financial arrangements or affiliations to disclose.

Participant has indicated no discussion of unapproved drug or product uses.